文献速递免疫规划慢病防控与筛查

重组疫苗接种的HIV感染者队列中带状疱疹再激活情况

Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine.
PubMed 文献 · Vaccine · 2025-09-09

该观察性研究纳入2022年1月至2023年12月接种重组带状疱疹疫苗(RZV)的223例≥18岁HIV感染者,在接种至少6个月后以问卷评估接种前后带状疱疹(HZ)及带状疱疹后神经痛(PHN)情况。145例可评估者中,接种前HZ患病率为37.24%(95%CI 29.36%-45.65%),接种后为8.97%(95%CI 4.86%-14.84%),接种后未记录到PHN病例;接种后HZ与年龄、血液系统、肿瘤及肝脏合并症相关。

要点

  • 145例可评估者中接种后HZ患病率8.97%(95%CI 4.86%-14.84%),接种后未记录到PHN病例。
  • 接种后HZ与年龄(OR 1.06,95%CI 1.01-1.13,P=0.031)及血液系统、肿瘤、肝脏合并症相关。
  • 未发现接种后HZ与病毒免疫学状态、HIV感染临床病史或合并用药存在关联。

核心结论

  • 作者称这是首个真实世界研究,显示HIV感染者接种RZV后临床反应良好,HZ再激活患病率低且接种后PHN完全消退。
  • 作者指出接种后HZ再激活与年龄及血液系统、肿瘤、肝脏合并症相关。

研究设计与样本

  • 观察性研究,纳入2022年1月至2023年12月所有接种RZV的≥18岁HIV感染者,共223例。
  • 接种至少6个月后以问卷询问既往HZ和PHN病史及接种后再发情况。
  • 收集人口学特征、合并症、病毒免疫学状态和用药,行描述性分析及单因素logistic回归。

主要发现

  • 145例可评估者中,接种前HZ 54例,患病率37.24%(95%CI 29.36%-45.65%);接种后HZ 13例,患病率8.97%(95%CI 4.86%-14.84%)。
  • 接种前PHN患病率19.23%(95%CI 11.18%-29.73%),平均NRS 6.33(95%CI 4.9-7.76);接种后未记录到PHN病例。
  • 接种后HZ与年龄相关(OR 1.06,95%CI 1.01-1.13,P=0.031)。
  • 接种后HZ与血液系统合并症相关(OR 9.60,95%CI 1.70-49.9,P=0.007)。
  • 接种后HZ与肿瘤合并症(OR 5.36,95%CI 1.04-22.8,P=0.028)及肝脏合并症(OR 3.67,95%CI 1.10-12.0,P=0.030)相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People living with HIV (PLWH) have a higher risk of herpes zoster (HZ) reactivation and postherpetic neuralgia (PHN) compared to general population. Our study aims to evaluate prevalence of HZ reactivation and PHN after vaccination with recombinant vaccine (RZV) in a population living with HIV, and to identify risk factors associated with recurrence. METHODS: We conducted an observational study, enrolling all PLWH ≥18 years old vaccinated with RZV from January 2022 to December 2023. A questionnaire was proposed to the subjects at least 6 months after vaccination, inquiring about previous history of HZ and PHN, and recurrence after vaccination. We collected demographic characteristics, comorbidities, viro-immunological status, and medications. We performed a descriptive analysis and univariate logistic regressions to investigate risk factors associated with HZ reactivation and PHN persistence. RESULTS: We included 223 subjects. We estimated the prevalence of events among 145 subjects: we recorded 54 subjects with pre-vaccination HZ (prevalence 37.24 % [IC 95 %: 29.36% - 45.65 %]) and 13 with post-vaccination HZ (prevalence 8.97 % [IC 95 %: 4.86 % - 14.84 %]). The prevalence of pre-vaccination PHN was 19.23 % [IC 95 %: 11.18 % - 29.73 %], with mean NRS 6.33 [IC 95 %: 4.9-7.76]; no case of PHN was recorded after vaccination. Evaluating risk factors related to post-vaccination HZ, we didn't find any association with viro-immunological status, clinical history of HIV infection, or concomitant medications. We correlate HZ and age (OR 1.06, CI 95 % 1.01-1.13, p-value 0.031), haematological (OR 9.60, CI 95 % 1.70-49.9, p-value 0.007), oncological (OR 5.36, CI 95 % 1.04-22.8, p-value 0.028), and hepatic comorbidities (OR 3.67, CI 95 % 1.10-12.0, p-value 0.030). CONCLUSIONS: This is the first real-world study that highlights the excellent clinical response to RZV, with a low prevalence of HZ reactivation and complete resolution of PHN after the vaccination. Moreover, we identified clinical conditions promoting the recurrence HZ after vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Arsuffi S, Rossi L, Colombo FR, et al. Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine. Vaccine. 2025. PMID: 40930046. doi:10.1016/j.vaccine.2025.127723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。